The invention discloses application of a metabonomics marker combination in preparation of a product for identifying benign and malignant
lung ground glass nodules. The metabonomics marker combination comprises the following 11 metabonomics markers: 5 '-S-methyl-5'-thioadenosine, 5 '-S-methyl-4'-thioadenosine, 5 '-S-methyl-4'-thioadenosine, 5 '-S-methyl-4'-thioadenosine, 5 '-S-methyl-4'- And gamma-glutamylglutamic acid; the component A is N-stearoyl-D-red
sphingosine;
sphingosine; palmitoyl
ethanolamide; 2-(4-(diethylamino) butyl-2-
alkyne-1-yl) isoindene-1, 3-
diketone is used as a
raw material; vesenadine;
zolpidem; the preparation method comprises the following steps: adding 4-hydroxyl-3-(2 '-hydroxyl-1, 1'-
biphenyl-4-yl)-6-oxo-6, 7-dihydrothieno [2, 3-b]
pyridine-5-formonitrile into a reaction kettle, and stirring for 20-30 minutes; and D-erythro-
sphingosine; the invention relates to 3-methylpyrrole-2, 4-
dicarboxylic acid. According to the invention, 11 specific
metabolic markers closely related to benign and malignant
lung ground glass nodules are found, the AUC value of a diagnosis model constructed on the basis of the 11
metabolic markers is up to 0.888, and the diagnosis model has extremely high identification accuracy and specificity.